Methods and compositions for treating eye disorders

• US 20040234532A1
• Filed: 05/20/2003
• Published: 11/25/2004
• Est. Priority Date: 05/20/2003
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: First, Eric R.
• Granted Patent: US 7,220,422 B2
• Time in Patent Office: Days
• US Class Current: 424/184.1
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators

Abstract

The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. The Clostridial toxin may be produced by a Clostridial beratti, a Clostridia butyricum, a Clostridial tetani bacterium and/or a Clostridial botulinum.

Claims

1. A method for treating an eye disorder comprising administering a Clostridial toxin to a cornea of a mammal to treat the eye disorder.

2. The method of claim 1 wherein the eye disorder is associated with an inflammation of the eye.

3. The method of claim 1 wherein the eye disorder is bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, or inflammation response after intra-ocular lens implantation.

4. The method of claim 1 wherein the eye disorder is conjunctivitis.

5. The method of claim 1 wherein the Clostridial toxin is administered topically to the cornea.

6. The method of claim 1 wherein the Clostridial toxin is produced by Clostridial beratti, Clostridia butyricum, Clostridial tetani bacterium or Clostridial botulinum.

7. The method of claim 1 wherein the Clostridial toxin is administered with a vasoconstrictor.

8. The method of claim 1 wherein Clostridial toxin is botulinum toxin types A, B, C₁, D, E, F, G or mixtures thereof.

9. The method of claim 1 wherein the Clostridial toxin is botulinum toxin type A.

10. The method of claim 8 wherein the eye disorder is associated with an inflammation of the eye.

11. The method of claim 8 wherein the eye disorder is bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation.

12. The method of claim 8 wherein the eye disorder is conjunctivitis.

13. The method of claim 8 wherein the Clostridial toxin is administered topically to the cornea.

14. The method of claim 8 wherein the Clostridial toxin is administered in conjunction with a vasoconstrictor.

15. A composition comprising:

an ophthalmically acceptable carrier;

a Clostridial toxin in an amount effective to treat an eye disorder when the composition is administered to an eye; and

a polyanionic component in an amount effective to provide lubrication to an eye when the composition is administered to an eye.

17. The composition of claim 17 wherein the Clostridial toxin is botulinum toxin type A.

16. The composition of claim 17 wherein the Clostridial toxin is botulinum toxin type A, B, C₁, D, E, F, G or mixtures thereof.

18. The composition of claim 17 wherein the polyanionic component comprises an anionic cellulosic derivative.

19. The composition of claim 17 wherein the polyanionic component comprises carboxy methyl celluloses.

20. The composition of claim 17 further comprising a vasoconstrictor.